ArticleInternational urology and nephrology2026
Initial non-curative treatment for favorable intermediate-risk prostate cancer.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the oncologic outcomes of intermediate-risk prostate cancer (FIR-PCa) patients receiving different initial treatment regimens as more FIR-PCa patients are now recommended for non-radical treatment due to the side effects of radical therapy.
methods8616 FIR prostate cancer patients were retrospectively evaluated using the Surveillance, Epidemiology, and End Results (SEER) database (2010-2015) and reported prostate cancer-specific survival (PCSS) for groups defined by the initial treatment category. Statistical analysis was performed using Pearson's chi-square test, Multivariate Cox proportional hazard regression, and Kaplan-Meier method.
resultsKaplan-Meier curves of PCSS revealed that non-curative treatment provided worse disease control than curative management for FIR-PCa patients (Hazard ratio 5.9061; 95% confidence interval 3.3398-10.4446; p < 0.0001). After adjusting for age at diagnosis, race, T stage, PSA level, and Gleason score, non-curative management was significantly associated with a decrease in PCSS (Adjusted hazard ratio 3.34; 95% CI 1.97-5.67; p = 0.0027).
conclusionPending prospective validation, our findings do not support a 'uniform' increment in current utilization practices for non-curative treatment strategies for FIR-PCa.
Indexed as
Identifiers
40866735What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.